Hypoxia-inducible factors (HIF) are essential transcriptional regulators that mediate adaptation to hypoxic stress in rapidly growing tissues such as tumors. HIF activity is regulated by hypoxic stabilization of the related HIF-1A and HIF-2A subunits, which are frequently overexpressed in cancer cells. To assess the relative tumor-promoting functions of HIF-1A and HIF-2A directly, we replaced HIF-1A expression with HIF-2A by creating a novel ''knock-in'' allele at the Hif-1a locus through homologous recombination in primary murine embryonic stem cells. Compared with controls, s.c. teratomas derived from knock-in embryonic stem cells were larger and more proliferative, had increased microvessel density, and exhibited increased expression of vascular endothelial growth factor, transforming growth factor-A, and cyclin D1. These and other data indicate that HIF-2A promotes tumor growth more effectively than HIF-1A in multiple contexts. (Cancer Res 2005; 65(6): 2277-86) 
Introduction
Oxygen deprivation (hypoxia) can occur in rapidly growing tissues, or as a consequence of disrupted blood flow, and can result in depletion of intracellular ATP stores, compromised ion transport, and altered cellular homeostasis (1) . Multicellular animals have evolved complex mechanisms that mediate adaptation to hypoxic stress during normal development, as well as in pathologic states such as ischemia and cancer. The master transcriptional regulators of both cellular and systemic hypoxic adaptation are the hypoxiainducible factors (HIF). HIF heterodimers consist of an a subunit (HIFa) and h subunit (HIFh, also known as aryl hydrocarbon receptor nuclear translocator; refs. 2, 3) . HIFs regulate the expression of at least 150 genes involved in metabolism, cell survival, erythropoiesis, and vascular remodeling (1) by binding to cis-acting hypoxia response elements located in the enhancers and/or promoters of these genes (4, 5) . The growing list of HIF target genes include those encoding important angiogenic factors such as vascular endothelial growth factor (VEGF) and plateletderived growth factor-h (6-10), as well as glycolytic enzymes, glucose transporters, and signaling molecules (1) .
HIF transcriptional activity is regulated primarily at the level of HIFa subunit stability. Under atmospheric O 2 conditions or ''normoxia'' (21% O 2 ), HIFa subunits are constitutively transcribed and translated, but rapidly ubiquitinated and degraded through direct interaction with an E3 ubiquitin ligase complex containing the von Hippel-Lindau tumor suppressor protein (11) (12) (13) (14) (15) . HIF-1a is expressed ubiquitously in human and mouse tissues, and has been proposed as the primary regulator of the hypoxic response (5, 16, 17) . The more recent identification of HIF-2a (also known as endothelial PAS domain protein 1, HIF-1-like factor, and HIF-1-related factor) has raised important questions about the relative activity of these factors in mediating hypoxic adaptation (18) (19) (20) . HIF-1a and HIF-2a share a high degree of sequence identity, which is underscored by their shared ability to heterodimerize with aryl hydrocarbon receptor nuclear translocator and bind hypoxia response elements to activate transcription in various in vitro reporter assays (18, 20) . In addition, both HIF-1a and HIF-2a are subject to posttranslational regulation mediated by the von Hippel-Lindau tumor suppressor protein (13, 21) . Interestingly, recent reports have indicated that HIF-1a and HIF-2a have partly, but not completely, overlapping sets of target genes. For example, whereas HIF-1a and HIF-2a both activate expression of VEGF, glucose transporter 1, and several other targets, only HIF-1a seems to regulate the hypoxic induction of genes encoding glycolytic enzymes (22, 23) .
Whereas HIF-1a is expressed ubiquitously, HIF-2a is expressed in a more spatially restricted pattern. For example, HIF-2a mRNA is expressed predominantly in endothelial cells, the mesenchyme of the lung, and neural crest derivatives during embryonic development (18) (19) (20) . Postnatally, HIF-2a protein has been detected specifically in bone marrow macrophages, kidney epithelial cells, liver parenchyma, cardiac myocytes, uterine decidual cells, and pancreatic parenchymal cells in hypoxic rats (24) . Genetic ablation of HIF-1a or HIF-2a has revealed dramatically different phenotypes, consistent with their differential expression patterns. HIF-1a null embryos die between embryonic days 8.5 and 10.5 (E8.5-E10.5), and display striking structural anomalies, including massive apoptosis of the neural mesenchyme and aberrant vasculature (6, 10) . In contrast, HIF-2a null embryos display a variety of phenotypes depending on genetic background; some embryos die at E13.5 due to bradycardia or hemorrhagic yolk sacs, whereas other HIF-2a null pups are born but die within days or weeks due to respiratory distress or general mitochondrial dysfunction (25) (26) (27) (28) . The degree to which these apparent functional differences between HIF-1a and HIF-2a are a consequence of disparate tissue-specific expression patterns, as opposed to differential target gene activation, is currently unknown.
Both HIF-1a and HIF-2a are expressed at high levels in a variety of human tumors and tumor cell lines (29, 30) , although the relative contribution of each protein to tumor initiation and progression is not yet clear. Mutational studies have shown that ES cells and transformed mouse embryonic fibroblasts lacking HIF-1a protein show diminished ability to generate s.c. teratomas and fibrosarcomas, respectively (10, 31) . Recent studies have also revealed an important role for HIF-2a in promoting the growth of xenografts derived from von HippelLindau tumor suppressor protein-deficient renal clear cell carcinomas (RCC; refs. [32] [33] [34] . Intriguingly, these experiments indicate that HIF-2a, but not HIF-1a, promoted the growth of these tumors, and that specific suppression of HIF-2a expression abrogated tumor growth (32) .
To fully understand the role of hypoxic adaptation in cancer biology, it will be important to dissect the specific roles of HIF1a and HIF-2a in tumor growth. Consequently, we have generated embryonic stem (ES) cells in which a cDNA encoding a c-Myc epitope-tagged HIF-2a was targeted into the first exon of the Hif-1a locus, generating a novel ''knock-in'' (KI) allele. This allele expresses HIF-2a under the control of the Hif-1a locus, but in a Hif-1a null background, thereby allowing a direct comparison of HIF-1a and HIF-2a when expressed under identical regulatory controls. In this report, we tested the ability of wild-type and homozygous KI ES cells to generate teratomas when injected s.c. into nude mice. Our experiments revealed that tumors derived from KI ES cells were more proliferative and more highly vascularized than wild-type tumors. Of note, tumor mass and microvessel density correlated with increased expression of the HIF-2a-regulated targets VEGF, cyclin D1 and transforming growth factor-a (TGF-a). Moreover, KI tumors displayed a distinctive spectrum of differentiated bone, cartilage, adipocyte, and neuronal (ganglia and Schwann cells) cell types, as well as an increased proportion of undifferentiated cells. Our study of the novel KI allele reveals inherent differential effects of HIF-1a and HIF-2a on tumor growth and cellular differentiation. Consistent with a previous report on renal cell carcinomas, our results further indicate that HIF-2a preferentially promotes tumor growth. diluted to generate single colonies, which were again assayed by Southern blot analysis to identify the final KI allele. Cell Lines. All ES cells were cultured in DMEM (Invitrogen) supplemented with 15% fetal bovine serum, 1% nonessential amino acids, 2% L-glutamine, 1% penicillin-streptomycin, leukemia inhibitory factor (ESGRO, Life Technologies, Temecula, CA), and 2-mercaptoethanol (Invitrogen, Carlsbad, CA). For Northern blot, electrophoretic mobility shift assay (EMSA), and Western blot analysis, ES cells were gelatin adapted on 10-cm plates and exposed to normoxia or hypoxia (1.5% O 2 ). The Hif-1a À/À ES cell line (37) was a kind gift from P. Carmeliet (Molecular and Cardiovascular Medicine Group, University of Leuven, Leuven, Belgium). Electrophoretic Mobility Shift Assay. EMSA analysis was done for HIF1a on nuclear extracts using a radiolabeled probe for the hypoxia response element of the erythropoietin promoter as previously described (38) . Briefly, 5 Ag of nuclear extracts were incubated with binding buffer, 0.05 mg/mL bovine serum albumin, 0.025 Ag/mL of cyclic AMP-responsive element binding protein oligo, and 10 6 dpm of labeled probe. HIF/DNA complexes were supershifted with HIF-1a antibody (Novus, Littleton, CO). Protein-DNA adducts were detected by phosphoimager analysis (Molecular Dynamics, Piscataway, NJ).
Materials and Methods

Generation
Immunoprecipitation and Western Blot Analysis. c-Myc epitopetagged HIF-2a protein was immunoprecipitated using a c-Myc polyclonal antibody (Cell Signaling, Inc., Beverly, MA) according to the manufacturer's protocol. Western blot analysis was done as previously described using HIF-1a or HIF-2a antibodies (38) . Primary antibodies were used at a dilution of 1:1,000. Secondary antibodies were horseradish peroxidase-conjugated, detected by enhanced chemiluminescence (Amersham, Piscataway, NJ), and exposed to autoradiographic film (Kodak, Rochester, NY).
Immunofluorescence. ES cells were grown on glass cover slips and exposed to hypoxia (1.5% O 2 ) for 4 hours or maintained in normoxia (20% O 2 ). Cells were fixed in 3% paraformaldehyde and permeabilized in 0.1% Triton in PBS. The Myc-epitope was detected with 9E10 monoclonal antibody (Abcam, Cambridge, MA). Cells were stained with FITCconjugated immunoglobulin-G (Vector Labs, Burlingame, CA). DNA was detected with Hoechst dye (Sigma, St. Louis, MO).
Mouse Teratoma Assay. ES cells (5 Â 10 6 ) in 100 AL of PBS were injected s.c. into the dorsal area of 4-to 6-week-old NIH-III immunodeficient mice (Charles River, Wilmington, MA). Tumors were measured every 2 to 3 days with calipers in the two greatest dimensions to calculate tumor growth over a 21-day period. At 21 days, tumors were harvested, photographed, weighed, fixed in 4% paraformaldehyde, and processed for histologic analysis.
Immunohistochemistry. Tumor samples were fixed in paraformaldehyde and paraffin-embedded by standard methods. Sections were stained by standard immunohistochemistry techniques with H&E or using antibodies generated against cleaved caspase-3 (Cell Signaling), Ki67 (Novocastra, United Kingdom), cyclin D1 (Calbiochem, San Diego, CA), CD34 (PharMingen, San Jose, CA), and VEGF (NeoMarkers, Fremont, CA). Secondary detection was done with biotinylated anti-mouse and anti-rat antibodies. Antibody staining was visualized using the avidin-biotin complex technique and 3,3V-diaminobenzidine (Vector Labs). Dilute hematoxylin was used for counterstain (Vector Labs). Morphometric analysis was done on three randomly chosen sections of each tumor (three tumors per genotype from each of the three independent experiments) using the analytical program Image Pro (Phase 3 Imaging) and by counting positive cells. For quantitative analysis of Ki67, cyclin D1, and cleaved caspase-3-staining, positive staining cells and microvessels were counted and their density expressed as the number of positive cells or capillaries per total section area, respectively. For quantitation of VEGF expression, the total positive staining area was calculated using the Image Pro software. Total number of cartilage, bone, Expanded HIF-2 a a Promotes Tumor Growth www.aacrjournals.org Schwann cell bundles, ganglia, and areas of fat were counted per slide and six slides (representing three independent experiments) were averaged together to quantitate differentiated tissues.
Tomato Lectin-FITC Labeling. Flourescein-Lycopersicon esculentum (tomato) lectin (100 AL; Vector Labs) were injected into the mouse tail vein at a dose of 2 mg/mL. Tumors were harvested, fixed in 4% paraformaldehyde, and paraffin-embedded.
Statistical Analysis. Statistical analyses were done by Student's t test. Statistical significance was defined as P < 0.05.
Quantitative Reverse Transcription-PCR. Total RNA was purified from wild-type and KI ES cells or teratomas using Trizol reagent (Life Technologies). Mixed Oligo-d(T) 15 and ribosomal 18S RNA-specific primers were used to generate single-stranded cDNAs, which were assayed for levels of VEGF-A, phosphoglycerate kinase (PGK), aldolase A (ALDA), TGF-a, adipose differentiation related protein (ADRP), cyclin D1 (CCND1), and 18S transcripts using an Applied Biosystems 7900HT Sequence Detection System. Mixed primer/probe sets for each transcript were obtained from Applied Biosystems and used according to the manufacturer's instructions. Expression levels of VEGF, PGK, ALDA, TGF-a, ADRP, and CCND1 transcripts were normalized to endogenous ribosomal 18S transcripts. Importantly, all gene expression data has been reproduced at least thrice. In Fig. 6D , RNA samples from two independent wild-type or KI teratomas were analyzed, pooled according to genotype, and comparisons made between genotypes by DDCt comparative analysis using manufacturer's software. (Fig. 1E) . Following identification of a correctly targeted clone, ES cells homozygous for the Hif-1a 2a allele were selected by treatment with increasing concentrations of G418 (Fig.  1E, lanes 5-7) .
Results
Generation of
We expected the homozygous Hif-1a 2a ES cells to be devoid of HIF-1a protein expression, as multiple stop codons exist in all three reading frames of the SV40 polyadenylation sequence placed immediately downstream of the cDNA in the targeting vector. However, initial characterization revealed that these cells expressed reduced levels of HIF-1a protein (Fig. 2A, lane 4) and failed to express the epitope-tagged HIF-2a protein (data not shown), raising the possibility that the PGK promoter of the NeoR cassette might interfere with proper expression of the HIF-2a cDNA transcript from the Hif-1a promoter. 5V-Rapid amplification of cDNA ends experiments confirmed this interpretation, demonstrating that a novel HIF-1a mRNA was transcribed in these cells, originating from the PGK promoter in the NeoR cassette (data not shown). This transcript contained an in-frame methionine codon 11 amino acids downstream of the initiator ATG, resulting in deletion of three lysine residues within the DNA binding domain. EMSA experiments also showed reduced HIF-1a DNA-binding activity in homozygous Hif-1a 2a ES cells, consistent with the reduced protein levels observed in the Western blot analysis (Fig. 2B, lanes 5-8) . Intriguingly, mice homozygous for this hypomorphic allele are viable and seem to be normal. 4 To activate expression of the HIF-2a-myc cDNA in the KI allele, the NeoR cassette was deleted in both heterozygous and homozygous ES cells through transient expression of Cre recombinase (Fig. 1F, lanes 3, 4, 6, and 7) . Deletion of the NeoR cassette removed the PGK promoter sequences driving expression of the novel HIF-1a transcript observed in the Hif-1a 2a cells. Further experiments revealed that ES cells homozygous for this recombined allele, designated ''KI'', exhibited no detectable HIF-1a protein by Western blot (Fig. 2A, lane 6 ) and EMSA analyses (Fig. 2B, lanes 9-12) . Hypoxic expression of the HIF-1a-specific target gene ALDA (22) was also reduced to levels observed in Hif-1a À/À cells, confirming the absence of any functional HIF-1a protein in KI ES cells (Fig. 2C) . Similar results were obtained for PGK, another HIF-1a-specific target gene (data not shown; ref. 22) . As HIF-2a protein is not readily alternate methods were employed to detect epitope-tagged HIF-2a protein in homozygous KI cells. Immunoprecipitation of cell extracts with a c-Myc epitope-specific antibody, followed by immunoblot analysis with HIF-2a antiserum, revealed that c-Myc-tagged HIF-2a protein is expressed and subject to oxygendependent regulation (Fig. 2D, lanes 3-8) . In addition, immunofluorescence experiments using the Myc antibody showed that the epitope-tagged HIF-2a protein is expressed in all KI cells and localized to the nucleus (Fig. 2E) . Together, these data indicate that HIF-1a expression has been replaced by HIF-2a in homozygous KI cells, and that Myc-tagged HIF-2a protein accumulation is regulated by O 2 levels.
Knock-in Allele Promotes Growth of Larger, More Hemorrhagic Tumors in Nude Mice. To investigate whether replacement of HIF-1a by HIF-2a could alter growth characteristics of ESderived teratomas, wild-type and homozygous KI ES cells were injected s.c. into NIH-III immunodeficient mice in three separate experiments (total n = 18 for each genotype). Teratomas appeared over a period of 10 to 21 days, but those generated from two independently derived KI ES cell lines grew more rapidly, exhibited increased mass, and seemed more hemorrhagic than wild-type controls (Fig. 3A-C) . The differences in mass were statistically significant (P = 0.012 by Student's t test). In contrast, KI and Hif-1a À/À ES cells showed essentially identical proliferation rates in vitro, whereas wild-type ES cells grew slightly faster (Fig. 3D) . Thus, the growth advantage noted for KI cells was only observed in the context of tumor growth. The expression of the Myc-tagged HIF-2a transcripts in KI tumors was confirmed by reverse transcription-PCR using allele-specific primers (data not shown).
To determine whether the difference in growth rates between wild-type and KI tumors was due to increased proliferation or decreased apoptosis, we analyzed teratomas by immunostaining for Ki67 and cleaved-caspase 3, respectively (Fig. 4) . In three independent experiments, KI tumors showed a 2.5-fold increase in Ki67 staining (Fig. 4A-C) , whereas no quantitative differences in cleaved-caspase 3 staining were observed between the two genotypes ( Fig. 4D-F) . As cyclin D1 expression is induced by hypoxia in RCC cells expressing HIF-2a (39), immunohistochemistry was done for cyclin D1 in wild-type and KI tumors. Overall, KI tumors showed increased nuclear cyclin D1 immunostaining compared with wild-type tumors (Fig. 4G-I) . Together, our data indicate that expanded HIF-2a expression, under the control of Knock-in Tumors Exhibit Increased Microvessel Density. Gross morphologic analysis revealed increased hemorrhaging of KI tumors (Fig. 3A) . Histologic analysis also revealed larger blood-filled cavities and hemangiomas in KI tumors compared with those derived from wild-type ES cells (compare Fig. 7A with B) . These data suggest that the KI allele promotes tumor angiogenesis. To assess the microvessel density of wild-type and KI teratomas, tumor sections were immunostained with an endothelial cell-specific marker, CD34 (Fig. 5A and B) . Quantitation of CD34 staining revealed an increased microvessel density in KI tumors (19.6 F 2.3/20Â field) compared with wild-type (8.8 F 1.6/20Â field; Fig. 5E ). Results are the averages of three independent experiments (three random sections of three different tumors for each genotype per experiment) and are statistically significant (P = 0.01 by Student's t test). The pattern of increased microvessel density in KI tumors is consistent with the increased vasculature observed in tumors from mice injected with fluorescently labeled tomato lectin ( Fig. 5C and D) .
Knock-in Tumors Display Increased VEGF and TGF-A Expression. We reasoned that the increased microvessel density and aberrant vessels observed in the KI tumors could reflect increased expression of angiogenic HIF target genes by HIF-2a. This idea is consistent with a previous report demonstrating that HIF-2a induces VEGF expression more potently than HIF-1a in Chinese hamster ovary Ka13 cells (40) . To test this hypothesis, we did immunohistochemical stains for VEGF (Fig. 6A and B) . KI tumors exhibited increased VEGF staining compared with wildtype tumors (Fig. 6C) . Furthermore, the VEGF expression pattern correlated with the observed differences in microvessel density, increased numbers of hemangiomas, gross hemorrhaging, and presence of endotheliomas (Fig. 7H) . These results suggest that the greater vascularity observed in KI tumors results at least partly from increased VEGF expression.
Quantitative reverse transcription-PCR analysis of tumor RNAs confirmed increased levels of VEGF transcripts in KI tumors, although the difference compared with wild-type tumors was modest (1.3 F 0.05-fold; Fig. 6D ). Intriguingly, expression of the HIF-2a target gene TGF-a (41) showed a substantial increase (3.05 F 0.06-fold) in the KI teratomas, raising the possibility that increased TGF-a expression in these tumors may be responsible, at least in part, for the phenotypes observed. In addition to VEGF and TGF-a, mRNA levels for the HIF-2a target gene ADRP (22) were also modestly increased (1.3 F 0.07-fold change) in KI tumors. Surprisingly, cyclin D1 transcript levels were slightly lower in KI tumors (0.87 F 0.05-fold), suggesting that the increase in cyclin D1 protein levels observed in KI tumors (Fig. 4) was caused by a posttranscriptional mechanism. Finally, the expression of PGK mRNA was significantly reduced (0.55 F 0.03-fold) in KI tumors relative to wild-type, consistent with previous reports that genes encoding glycolytic enzymes are regulated only by HIF-1a, but not by HIF-2a (22, 23) . The differences between VEGF and cyclin D1 transcript and protein levels in KI tumors may reflect the indirect effects of expanded HIF-2a expression, as discussed below.
Knock-in Tumors Exhibit a Wide Range of Differentiated Cell Types. To investigate the degree of differentiation and spectrum of cell types present, tumor sections were evaluated by standard histologic methods. As expected, wild-type tumors exhibited tissues derived from all three germ layers. In addition, wild-type tumors contained predominately neuroectodermal lineages characterized by oval-shaped nuclei arranged in radiating rosettes (Fig. 7A) . KI tumors differed from wild-type tumors in two notable ways: (a) KI tumors exhibited an expansion of apparently undifferentiated cells (Fig. 7B) , and (b) KI tumors showed a substantial increase in specific highly differentiated structures (Fig. 7C) . Compared with wild-type controls, KI tumors displayed 5-to 10-fold more cartilage, bone, neuronal cell types (Schwann cell and ganglia), fat cells, and endotheliomas (Fig. 7D-I ).
Discussion
A great deal of work over the past 10 years has shown that hypoxia is a critical factor regulating angiogenesis and cellular metabolism in tumors (30) . The hypoxically regulated transcription factors HIF-1a and HIF-2a are overexpressed in a large number of human tumor types, including brain, prostate, breast, RCC, pheochromocytomas, astrocytomas, and non-small cell lung cancers (21, (42) (43) (44) , consistent with the idea that each contributes to tumor growth by activating the expression of critical target genes. Although both HIF-1a and HIF-2a are expressed in many of the same human tumors and tumor cell lines (29, 45) , the relative contribution of each protein to tumor initiation and progression has been difficult to determine. Genetic ablation experiments have confirmed a role for both proteins in tumor growth; for example, s.c. tumors derived from Hif-1a À/À mouse embryonic fibroblasts and ES cells grew less rapidly than wild-type controls (10, 31) . More recently, Kondo et al. (33) and Maranchie et al. (34) used complementary experimental approaches to show that expression of HIF-2a, but not HIF-1a, promoted the growth of RCC xenografts. In particular, it was shown that inhibition of HIF-2a is sufficient to suppress tumor formation by a RCC line lacking the von HippelLindau tumor suppressor protein (32) . The apparently unique activity of HIF-2a in promoting the growth of RCC, and possibly other tumors, could represent differences in the cell type-specific expression patterns of HIF-1a and HIF-2a, and/or differences in the spectrum of target genes they regulate. Clarifying this issue will be critical for understanding the mechanisms by which hypoxia affects the progression of many cancers.
To better distinguish the unique biological activities conferred by HIF-1a and HIF-2a in tumor growth and embryonic development, we created a KI allele of the murine Hif-1a gene. In this allele, a HIF-2a cDNA clone was introduced into the Hif-1a genomic locus, thereby replacing HIF-1a expression with HIF-2a. This novel allele permits a direct comparison of how HIF-1a and HIF-2a function when expressed independently, but under the influence of the same cis-acting regulatory sequences, in primary cells. In this report, we used the KI allele to investigate the relative contribution of HIF-1a and HIF-2a to the growth of ES cell-derived teratomas. This approach avoids the use of transgene constructs, which may produce nonphysiologic expression levels or patterns, or transformed cells in which confounding oncogenic mutations can dysregulate or override HIF function. Although a full appreciation of HIF-1a and HIF-2a function in human cancers will ultimately require an understanding of their interaction with other oncogenic mutations, these experiments represent an important step toward dissecting their unique and shared activities in tumor biology.
The enhanced proliferative and vascular phenotypes observed in KI tumors probably reflect the expanded and augmented expression of specific HIF-2a transcriptional targets, relative to wild-type cells. As multiple analyses have shown that HIF-2a regulates VEGF, cyclin D1, and TGF-a in RCC carcinoma lines (39, 41) and ADRP in HEK293 cells (22) , the simplest model to explain our data would invoke direct transcriptional activation of these and other target genes by HIF-2a in the KI tumors. Immunohistochemical analysis indeed revealed increased VEGF and cyclin D1 protein expression, as well as modestly increased VEGF and ADRP mRNA expression in KI tumors. Cyclin D1 mRNA levels were, paradoxically, slightly decreased in these tumors, suggesting that the increased nuclear expression of cyclin D1 results from posttranscriptional mechanisms such as increased protein stability, as previously described (46) . Whereas HIF-1a-specific target genes ALDA and PGK were significantly downregulated in KI tumors, transcripts from other target genes previously shown to be common targets of HIF-1a and HIF-2a, including glucose transporter 1 and adrenomedullin 1, were expressed at nearly identical levels in wild-type and KI teratomas (data not shown). In contrast, TGF-a transcript levels were dramatically increased in KI tumors, suggesting that this target gene may be preferentially induced by HIF-2a. Together, these data indicate that the phenotype of the KI cells was not simply due to loss of HIF-1a function, but resulted from expanded expression of HIF-2a under the control of the HIF-1a locus. Moreover, the results Figure 7 . Increased differentiation in KI teratomas. A-H, H&E staining of wild-type (A ) and KI (B-H ) teratomas. A, primitive neuroectoderm in wild-type teratomas. Endodermal and mesodermal derivatives were also observed in different sections. KI teratomas (B-H ) contained regions marked either highly undifferentiated cells (B) or highly differentiated tissues (C ) such as cartilage (D ), bone (E), Schwann cells, ganglia (F ), and adipocytes (G ). H&E staining also revealed increased hemangioma (B) and endothelioma (H ). n, neuroectoderm; c, cartilage; b, bone; s, Schwann cells; g, ganglia; f, fat; h, hemangiomas (arrowheads ). I, quantitation of differentiated tissues in wild-type and KI teratomas (see Materials and Methods).
reported here indicate that the preferential tumor-promoting effects of HIF-2a previously reported for RCCs (32) are more generally applicable.
Our data show clear differences between KI and wild-type ES cells that correlate to expression of the HIF-2a cDNA from the Hif1a locus. Although HIF activity is primarily controlled at the level of protein stabilization, it is possible that the expression of a targeted cDNA may modulate overall expression of the locus, thereby affecting the phenotype of the cells. To address this concern, we recently generated ES cells in which the HIF-1a cDNA has been targeted to the Hif-1a locus in a manner identical to the HIF-2a cDNA. Preliminary data indicate that ES cells homozygous for this HIF-1a cDNA KI allele express ALDA, VEGF, and TGF-a transcripts at levels similar to wild-type ES cells, in stark contrast to the HIF-2a KI cells. Furthermore, these HIF-1a cDNA KI cells behave essentially identically to wild-type ES cells in their ability to generate hematopoietic progenitors from embryoid bodies, an assay in which the HIF-2a KI cells are strikingly deficient (data not shown). These and other preliminary data support our interpretation that the phenotypes exhibited by the HIF-2a KI ES cells are due to functional differences between HIF-1a and HIF-2a, and are not simply a consequence of expressing a targeted cDNA from the Hif-1a locus. Definitive conclusions, however, will require further comparison of HIF-1a KI and HIF-2a KI ES cells.
It is possible that the phenotypes observed for the KI teratomas result, at least in part, from indirect effects of expanded HIF-2a expression. The increase in TGF-a mRNA levels in KI tumors is of particular interest in this regard, as overexpression of TGF-a has been shown to profoundly affect cellular proliferation and differentiation (47) (48) (49) . TGF-a expression has been correlated to increased cyclin D1 expression in a variety of cellular contexts (50, 51) , and also to increased tumor microvessel density (52, 53) . It is therefore possible that TGF-a signaling through the epidermal growth factor receptor may be a critical downstream effector of HIF-2a with respect to VEGF and cyclin D1 protein accumulation.
It is noteworthy that the hypoxia-induced expression of TGF-a in RCC cells that express HIF-2a (but not HIF-1a) is critical for the serum-independent growth of these cells (41) . Further work will be required to thoroughly evaluate the effects of HIF-2a-mediated TGF-a expression on tumor initiation and growth.
The particular spectrum and abundance of bone, cartilage, and neural cells observed in the KI teratomas raises questions about the activity of HIF-2a in multiple developmental pathways. Genetic ablation of HIF-2a does not seem to disrupt the development of these tissues (25) (26) (27) , perhaps because HIF-1a can compensate for the loss of HIF-2a in these cell lineages. In contrast, our results suggest that when HIF-2a is broadly expressed in lieu of HIF-1a, the balance of signals controlling cellular differentiation is altered. Whether this imbalance results from markedly increased expression of particular HIF-2a targets such as TGF-a, or from more subtle changes in a wide range of HIF target genes, will be an important question to address in future work. Irrespective of the mechanisms, it would seem that expanded HIF-2a expression from the KI allele promotes differentiation of bone, cartilage, adipocytes, and endothelial structures from ES cells. A thorough evaluation of HIF target gene expression in differentiated primary cells carrying the KI allele may help to further distinguish the unique and overlapping functions of HIF-1a and HIF-2a in development and tumor progression.
